3/21
07:14 pm
rlmd
Relmada Therapeutics: Run Up Into Results May Resume Following This Drop [Seeking Alpha]
Low
Report
Relmada Therapeutics: Run Up Into Results May Resume Following This Drop [Seeking Alpha]
3/20
10:33 am
rlmd
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/19
04:19 pm
rlmd
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results [Yahoo! Finance]
High
Report
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results [Yahoo! Finance]
3/19
04:15 pm
rlmd
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
High
Report
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
3/12
07:30 am
rlmd
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
Medium
Report
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
3/5
07:44 am
rlmd
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference [Yahoo! Finance]
Low
Report
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference [Yahoo! Finance]
3/5
07:30 am
rlmd
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Low
Report
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
3/4
05:53 am
rlmd
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth? [Yahoo! Finance]
Medium
Report
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth? [Yahoo! Finance]
3/19/2024
04:15 pm
rlmd
relmada therapeutics, inc.
BEAT
Report
-17.4%
relmada therapeutics, inc.
11/8/2023
04:01 pm
rlmd
relmada therapeutics, inc.
BEAT
Report
-0.3%
relmada therapeutics, inc.
8/8/2023
04:01 pm
rlmd
relmada therapeutics, inc.
BEAT
Report
7.1%
relmada therapeutics, inc.
5/11/2023
04:04 pm
rlmd
relmada therapeutics, inc.
BEAT
Report
-6.3%
relmada therapeutics, inc.
4/9
04:15 pm
rlmd
Form DEFA14A RELMADA THERAPEUTICS,
Medium
Report
Form DEFA14A RELMADA THERAPEUTICS,
4/9
04:11 pm
rlmd
Form DEF 14A RELMADA THERAPEUTICS, For: May 24
Medium
Report
Form DEF 14A RELMADA THERAPEUTICS, For: May 24
3/19
04:11 pm
rlmd
Form 8-K RELMADA THERAPEUTICS, For: Mar 19
High
Report
Form 8-K RELMADA THERAPEUTICS, For: Mar 19
3/19
04:06 pm
rlmd
Form 10-K RELMADA THERAPEUTICS, For: Dec 31
High
Report
Form 10-K RELMADA THERAPEUTICS, For: Dec 31
2/20
05:56 pm
rlmd
Form 144 RELMADA THERAPEUTICS, Filed by: O'Gorman Cedric
Medium
Report
Form 144 RELMADA THERAPEUTICS, Filed by: O'Gorman Cedric
2/14
08:54 am
rlmd
Form SC 13G/A RELMADA THERAPEUTICS, Filed by: Deep Track Capital, LP
Low
Report
Form SC 13G/A RELMADA THERAPEUTICS, Filed by: Deep Track Capital, LP
2/14
07:50 am
rlmd
Form SC 13G/A RELMADA THERAPEUTICS, Filed by: RTW INVESTMENTS, LP
High
Report
Form SC 13G/A RELMADA THERAPEUTICS, Filed by: RTW INVESTMENTS, LP
2/13
05:19 pm
rlmd
Form SC 13G/A RELMADA THERAPEUTICS, Filed by: VANGUARD GROUP INC
Medium
Report
Form SC 13G/A RELMADA THERAPEUTICS, Filed by: VANGUARD GROUP INC
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd lot
Avg. bid-ask spread
Avg. bid-ask size
Shares at ask/bid
Off exchange
Main News & Impact Reports
10/14
Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15
134.0%
10/18
Form 8-K RELMADA THERAPEUTICS, For: Oct 17
52.4%
12/4
Relmada prices $100M equity offering [Seeking Alpha]
49.8%
3/18
Form 4 RELMADA THERAPEUTICS, For: Mar 17 Filed by: CASAMENTO CHARLES J
14.7%
3/16
Form 3 RELMADA THERAPEUTICS, For: Mar 09 Filed by: Wessel Thomas
10.6%
10/28
Form S-3/A RELMADA THERAPEUTICS,
10.5%
3/24
Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development
10.0%
5/16
Form D RELMADA THERAPEUTICS,
8.2%
3/31
Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety
7.4%
5/15
Form 4 RELMADA THERAPEUTICS, For: May 14 Filed by: Kelly Paul Edward
7.1%
10/17
Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18
-18.0%
6/20
Form 8-K RELMADA THERAPEUTICS, For: Jun 14
-16.0%
10/21
Form 8-K RELMADA THERAPEUTICS, For: Oct 15
-12.3%
7/10
Form D/A RELMADA THERAPEUTICS,
-10.5%
1/31
Form DEF 14A RELMADA THERAPEUTICS, For: Mar 06
-9.7%
3/9
Form 8-K RELMADA THERAPEUTICS, For: Mar 06
-8.7%
3/9
Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development
-8.6%
10/24
Form EFFECT RELMADA THERAPEUTICS,
-7.1%
5/1
Relmada Therapeutics Inc (OTCMKTS: RLMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.
-6.0%
4/21
Relmada Therapeutics Inc (OTCMKTS: RLMD) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock.
-6.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Register